These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16890580)

  • 1. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
    Gardner ER; Burger H; van Schaik RH; van Oosterom AT; de Bruijn EA; Guetens G; Prenen H; de Jong FA; Baker SD; Bates SE; Figg WD; Verweij J; Sparreboom A; Nooter K
    Clin Pharmacol Ther; 2006 Aug; 80(2):192-201. PubMed ID: 16890580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
    Takahashi N; Miura M; Scott SA; Kagaya H; Kameoka Y; Tagawa H; Saitoh H; Fujishima N; Yoshioka T; Hirokawa M; Sawada K
    J Hum Genet; 2010 Nov; 55(11):731-7. PubMed ID: 20720558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan pathway genotype analysis to predict pharmacokinetics.
    Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
    Burger H; van Tol H; Brok M; Wiemer EA; de Bruijn EA; Guetens G; de Boeck G; Sparreboom A; Verweij J; Nooter K
    Cancer Biol Ther; 2005 Jul; 4(7):747-52. PubMed ID: 15970668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
    Liu W; Baer MR; Bowman MJ; Pera P; Zheng X; Morgan J; Pandey RA; Oseroff AR
    Clin Cancer Res; 2007 Apr; 13(8):2463-70. PubMed ID: 17438106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib.
    Burger H; Nooter K
    Cell Cycle; 2004 Dec; 3(12):1502-5. PubMed ID: 15611623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
    van Erp NP; Gelderblom H; Karlsson MO; Li J; Zhao M; Ouwerkerk J; Nortier JW; Guchelaar HJ; Baker SD; Sparreboom A
    Clin Cancer Res; 2007 Dec; 13(24):7394-400. PubMed ID: 18094422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
    Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
    Théou N; Gil S; Devocelle A; Julié C; Lavergne-Slove A; Beauchet A; Callard P; Farinotti R; Le Cesne A; Lemoine A; Faivre-Bonhomme L; Emile JF
    Clin Cancer Res; 2005 Nov; 11(21):7593-8. PubMed ID: 16278376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.
    Takahashi N; Miura M
    Pharmacology; 2011; 87(5-6):241-8. PubMed ID: 21474977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.